NewsBite

James Kirby

James Kirby
James KirbyWealth Editor

James Kirby, The Australian’s Wealth Editor, is one of Australia’s most experienced financial journalists. He is a former managing editor and co-founder of Business Spectator and Eureka Report and has previously worked at the Australian Financial Review and the South China Morning Post. He is a regular commentator on radio and television, he is the author of several business biographies and has served on the Walkley Awards Advisory Board. James hosts The Australian’s Money Puzzle podcast.

Latest

Money Puzzle podcastWealth
(FILES) This photograph taken on February 23, 2023, in Paris, shows the anti-diabetic medication "Ozempic" (semaglutide) made by Danish pharmaceutical company "Novo Nordisk". Surging demand for diabetes and weight loss drugs Ozempic and Wegovy has propelled Danish pharma group Novo Nordisk to the top spot as Europe's most valuable company, giving Denmark's economy a major makeover. (Photo by JOEL SAGET / AFP)

The Ozempic effect

The weight loss drug is causing market value losses at healthcare leaders such as CSL and ResMed – but when will the market pay attention to the limits of what Ozempic may offer?

Original URL: https://www.theaustralian.com.au/author/james-kirby/page/18